Recognition Highlights the Role of Multimodal AI in Improving Development Decisions, Reducing Risk and Accelerating Patient Impact

BostonGene, developer of the leading AI model for tumor and immune biology, today announced it has been named a Diamond winner in the 2026 Pinnacle Awards for Healthcare. Recognized in the Innovator in Biotech Solutions category, BostonGene was honored for its work in enabling better decision-making across drug development.

The Pinnacle Awards celebrate global excellence and innovation, highlighting organizations that are advancing medical technology and redefining care delivery. The Diamond tier recognition underscores BostonGene’s commitment to improving how critical drug development decisions are made, with direct impact on clinical success, cost, and time to patients.

Drug development is a sequence of high-stakes decisions: what to build, which patients to treat, and how to design and execute trials. BostonGene addresses this by modeling disease as a dynamic biological system and simulating how tumors and the immune system respond to therapeutic intervention. By integrating real multimodal data, including genomic, transcriptomic, immune, clinical, and imaging signals, BostonGene enables pharmaceutical teams to make more informed decisions before clinical trials begin.

This approach allows partners to identify optimal indications, refine patient selection, design more effective trials, and better understand mechanisms of response and resistance. The result is a shift from retrospective analysis to forward-looking decision-making, improving probability of success while reducing development cost and risk.

“This recognition reflects a broader shift in the industry,” said Andrew Feinberg, President and CEO at BostonGene. “Drug development is not a data problem, it is a decision problem. By modeling biology and simulating response to treatment, we help our partners make better decisions before trials begin, which is where outcomes are determined.”

About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260609592045/en/

“Drug development is not a data problem, it is a decision problem. By modeling biology and simulating response to treatment, we help our partners make better decisions before trials begin, which is where outcomes are determined.”